Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Post by Sarb99on Nov 23, 2020 6:28pm
838 Views
Post# 31957496

QuestCap is on the path be become an example

QuestCap is on the path be become an exampleAs picture posted on https://twitter.com/quest_cap/status/1330914848155242499 people waiting in the lineup to get tested. We can also see on collection sites appointment system. Most of these collection sites are remarkably busy performing covid-19 testing. QuestCap is already generating revenue compare to many others. QuestCap is also have a plan for testing, then vaccination then life after pandemic.  
 
Here is math, not pumping, I am even under estimating compare to those lineups and appointment system. I am going to say each collection site perform 125 test each day. 22x125 total daily test performed 2750. Now QuestCap charge $59 for Antibody, $99 for antigen then $179 for PCR, which is needed for travel. We will just pick average $75 per test.
 
2750x$75 =$206,250 daily revenue and $6,187,500 per month and $74 million per year.
 
If you calculate each site perform 150 test each day or some even 170 then these revenue number should be higher. Now lets say by the end of December QuestCap install 416+ testing sites then these revenue numbers are huge. As most us brought QSC under $.20 cents, I think reward for us can be huge.
 
As per our risk, revenue from these 22 sites of $74.25 million with 50% profit margin is $37.12 million and we can easily time it by 5. So, market cap with alone with these 22 sites should be somewhere $150 to $185 Million. So, at these prices, we are taking no risk other than wait. 
<< Previous
Bullboard Posts
Next >>